Achieving substantial weight reduction has historically required a combination of rigorous discipline and, more recently, the daunting prospect of weekly self-administered injections. This shift toward pharmacological intervention has been revolutionary, yet many individuals remain hesitant to
The European Commission’s recent authorization of AstraZeneca’s Imfinzi marks a significant shift in the therapeutic landscape for patients battling resectable gastric and gastro-esophageal junction cancers across the continent. This decision formalized the use of durvalumab as a perioperative
Ivan Kairatov is a titan in the biopharmaceutical sector, renowned for his deep expertise in the evolution of antibody-drug conjugates (ADCs). With a career spanning decades of research and development, he has been at the forefront of navigating the complex intersection of biotechnology and
Ivan Kairatov is a seasoned biopharma expert with a distinguished background in research and development, focusing specifically on the intersection of immunology and biotechnology. With years of experience analyzing the clinical and commercial trajectories of next-generation therapies, he has
We are joined by Ivan Kairatov, a biopharma expert with deep insights into the intricate world of drug research and development. In our conversation, we’ll explore the high-stakes landscape of regulatory approvals, touching on Bristol Myers Squibb's pivotal new cancer therapy, the challenging path
With a major breakthrough in psychedelic medicine, Compass Pathways' psilocybin-based therapy, COMP360, has delivered compelling Phase 3 results, sending shockwaves through the biopharma world and reigniting hope for patients with treatment-resistant depression. To unpack what this means for
